DE60024830D1 - Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen - Google Patents

Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen

Info

Publication number
DE60024830D1
DE60024830D1 DE60024830T DE60024830T DE60024830D1 DE 60024830 D1 DE60024830 D1 DE 60024830D1 DE 60024830 T DE60024830 T DE 60024830T DE 60024830 T DE60024830 T DE 60024830T DE 60024830 D1 DE60024830 D1 DE 60024830D1
Authority
DE
Germany
Prior art keywords
sub
substituted urea
heteroaryl substituted
urea bonding
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024830T
Other languages
English (en)
Other versions
DE60024830T2 (de
Inventor
Lin-Hua Zhang
Lei Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of DE60024830D1 publication Critical patent/DE60024830D1/de
Application granted granted Critical
Publication of DE60024830T2 publication Critical patent/DE60024830T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60024830T 1999-07-09 2000-06-27 Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen Expired - Lifetime DE60024830T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14309499P 1999-07-09 1999-07-09
PCT/US2000/017655 WO2001004115A2 (en) 1999-07-09 2000-06-27 Novel process for synthesis of heteroaryl-substituted urea compounds

Publications (2)

Publication Number Publication Date
DE60024830D1 true DE60024830D1 (de) 2006-01-19
DE60024830T2 DE60024830T2 (de) 2006-06-14

Family

ID=22502581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024830T Expired - Lifetime DE60024830T2 (de) 1999-07-09 2000-06-27 Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen

Country Status (9)

Country Link
US (5) US6583282B1 (de)
EP (1) EP1200411B1 (de)
JP (1) JP4162406B2 (de)
AT (1) ATE312823T1 (de)
CA (1) CA2374737C (de)
DE (1) DE60024830T2 (de)
ES (1) ES2253233T3 (de)
MX (1) MXPA02000314A (de)
WO (1) WO2001004115A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) * 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
CA2374737C (en) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6492393B1 (en) * 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2002007772A2 (en) * 2000-07-24 2002-01-31 Boehringer Ingelheim Pharmaceuticals, Inc. Improved oral dosage formulations
JP2004518739A (ja) 2001-02-15 2004-06-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法
MXPA03009361A (es) * 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
EP1709965A3 (de) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methode zur Behandlung von zytokinvermittelten Erkrankungen
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
ES2299689T3 (es) * 2002-02-25 2008-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas.
US7056925B2 (en) 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
US20040138216A1 (en) * 2002-12-23 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
WO2004113352A1 (en) * 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silylated heterocyclylurea derivatives as cytokine-inhibitors
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
KR101024904B1 (ko) * 2003-08-14 2011-03-31 엘지전자 주식회사 기록매체, 기록방법, 기록장치 및 기록재생시스템
BRPI0414313A (pt) * 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
JP2007514791A (ja) * 2003-12-18 2007-06-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐ３８ｍａｐキナーゼインヒビターであるｂｉｒｂ７９６の多形
EP2295427A1 (de) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituierte Pyrazolyl-harnstoff-derivate zur Behandlung von Krebs
ES2686357T3 (es) 2004-06-17 2018-10-17 Cytokinetics, Inc. Compuestos, composiciones y procedimientos
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
DE102005048390A1 (de) * 2005-10-10 2007-04-19 Siemens Ag Verfahren und Einrichtung zur Bewegungsführung eines bewegbaren Maschinenelementes einer Maschine
KR101310525B1 (ko) 2005-10-11 2013-09-23 가부시키가이샤 니콘 다층막 반사경, 다층막 반사경의 제조 방법, 광학계, 노광장치 및 디바이스의 제조 방법
US20070197505A1 (en) * 2005-12-15 2007-08-23 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
JP5301284B2 (ja) 2005-12-15 2013-09-25 サイトキネティクス・インコーポレーテッド 特定の化学物質、組成物および方法
EP1959962A2 (de) * 2005-12-16 2008-08-27 Cytokinetics, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
CN101415685B (zh) * 2006-01-31 2011-08-24 阿雷生物药品公司 激酶抑制剂及其使用方法
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CN102256964A (zh) 2008-10-02 2011-11-23 瑞斯比维特有限公司 p38MAP激酶抑制剂
MX2011006220A (es) 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
EP2578582A1 (de) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) Harnstoffe als p38 MAP Kinasehemmer
WO2013050757A1 (en) 2011-10-03 2013-04-11 Respivert Limited 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
CN103974953B (zh) 2011-12-09 2016-06-29 奇斯药制品公司 激酶抑制剂
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EP2890701B1 (de) 2012-08-29 2017-03-29 Respivert Limited Kinaseinhibitoren
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
EP2970190A1 (de) 2013-03-14 2016-01-20 Respivert Limited Kinaseinhibitoren
KR102340654B1 (ko) 2013-04-02 2021-12-16 옥슬러 액퀴지션즈 리미티드 키나제 저해제
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
CA2934199A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
MX371312B (es) 2014-02-14 2020-01-24 Respivert Ltd Pirazolil-ureas como inhibidores de quinasas.
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA44607A (fr) 2016-04-06 2021-05-19 Oxular Acquisitions Ltd Inhibiteurs de kinase
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109053623B (zh) * 2018-08-27 2020-08-04 济南悟通生物科技有限公司 一种4-甲基-5-噻唑甲醛的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US447624A (en) * 1891-03-03 Corn-harvester
US3291808A (en) * 1961-08-14 1966-12-13 Parke Davis & Co Naphthalene diamine compounds and methods for their production
US4105766A (en) 1977-08-19 1978-08-08 Sterling Drug Inc. 4,5-Dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acid derivatives
US4447624A (en) * 1980-08-27 1984-05-08 Eastman Kodak Company Preparation of thiophenes
HU185294B (en) 1980-12-29 1984-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing substituted urea derivatives
US4436567A (en) * 1982-03-22 1984-03-13 Weikert Roy J Method for joining webs of aseptic pouches
JPS61228444A (ja) 1985-04-02 1986-10-11 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
EP0272866A1 (de) 1986-12-23 1988-06-29 Merck & Co. Inc. 1,4-Benzodiazepine mit 5-gliedrigen heterocyclischen Ringen
GB8908869D0 (en) 1989-04-19 1989-06-07 Shell Int Research A process for the preparation of aromatic ureas
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
DD293352A5 (de) 1990-04-06 1991-08-29 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von 2,2-disubstituierten 1-acyl- und/oder 9-acyl-2,3-dihydro-imidazo/1,2-a/benzimidazol-3-onen
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
CA2134359C (en) 1992-05-28 1997-07-01 Ernest S. Hamanaka New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
WO1994022872A1 (en) 1993-03-30 1994-10-13 Yoshitomi Pharmaceutical Industries, Ltd. Cell adhesion inhibitor and thienotriazolodiazepine compound
WO1995007922A1 (en) 1993-09-17 1995-03-23 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
WO1996025157A1 (en) 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
EP0859771A4 (de) 1995-10-31 2000-03-15 Merck & Co Inc Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung
US6074862A (en) 1995-12-20 2000-06-13 Signal Pharmaceuticals Inc. Mitogen-activated protein kinase kinase MEK6 and variants thereof
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
EP0889887A4 (de) 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1997044467A1 (en) 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
JP2001501481A (ja) 1996-10-09 2001-02-06 メディカル、リサーチ、カウンシル Ｍａｐキナーゼ：ポリペプチド、ポリヌクレオチドおよびその使用
US6043246A (en) 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6376214B1 (en) 1997-02-18 2002-04-23 Smithkline Beecham Corporation DNA encoding a novel homolog of CSBP/p38 MAP kinase
ES2153337T3 (es) 1997-05-23 2008-11-01 Bayer Pharmaceuticals Corporation Inhibidores de la quinasa raf.
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US5851812A (en) 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US5858041A (en) * 1997-08-22 1999-01-12 David Luetkemeyer Clean air system
CA2223075A1 (en) 1997-12-02 1999-06-02 Smithkline Beecham Corporation Drug binding protein
NZ505845A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
PT1042305E (pt) 1997-12-22 2005-10-31 Bayer Pharmaceuticals Corp Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
EP1043995B9 (de) 1997-12-22 2008-10-08 Bayer Pharmaceuticals Corp. INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
CN1511830A (zh) 1999-03-12 2004-07-14 ���ָ��.Ӣ��ķҩ�﹫˾ 作为消炎剂的化合物
DE60023853T2 (de) * 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
CA2374737C (en) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds

Also Published As

Publication number Publication date
CA2374737C (en) 2008-02-12
US20030181718A1 (en) 2003-09-25
US6774233B2 (en) 2004-08-10
WO2001004115A3 (en) 2001-09-27
ATE312823T1 (de) 2005-12-15
US6583282B1 (en) 2003-06-24
US6835832B2 (en) 2004-12-28
JP4162406B2 (ja) 2008-10-08
JP2003504366A (ja) 2003-02-04
EP1200411A2 (de) 2002-05-02
US6753426B2 (en) 2004-06-22
ES2253233T3 (es) 2006-06-01
US20030109703A1 (en) 2003-06-12
EP1200411B1 (de) 2005-12-14
DE60024830T2 (de) 2006-06-14
US6894173B2 (en) 2005-05-17
US20030166930A1 (en) 2003-09-04
US20030166931A1 (en) 2003-09-04
CA2374737A1 (en) 2001-01-18
WO2001004115A2 (en) 2001-01-18
MXPA02000314A (es) 2004-06-22

Similar Documents

Publication Publication Date Title
DE60024830T2 (de) Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
CA2389360A1 (en) Urea derivatives as anti-inflammatory agents
MY128063A (en) Aromatic heterocyclic compound as antiinflammatory agents
ATE386030T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
CA2361998A1 (en) Aromatic heterocyclic compounds as anti-inflammatory agents
WO2003097656A3 (en) Novel substituted sulfamate anticonvulsant derivatives
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
TR28332A (tr) Arilasetik asit türevleri.
DE602004025344D1 (de) Biologisch abbaubare verzweigte polylactidderivate, die zur bildung von polymermicellen befähigt sind, herstellungsverfahren dafür und verwendung davon
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
WO2003042169A3 (en) Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
EA200300066A1 (ru) Производные аминоалкоксибензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
WO2004033423A3 (en) Anticancer compounds
RS88704A (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof
DE60318320D1 (de) Benzimidazolone und ihre verwendung als cytokininhibitoren
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
TR200000536A2 (tr) Büyüme hormonu sekretagogları hazırlamak için proses.
ATE446952T1 (de) Herstellungsverfahren von 2-cyanopyridinen
PT1373218E (pt) Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina
WO2003070696A3 (de) Substituierte arylketone
BR9910370A (pt) Compostos de cefalosporina, processo para preparar compostos de cefalosporina, e, composições antimicrobianas
WO2023239906A3 (en) Sialic acid derivatives and methods of using same
DE50107619D1 (de) Verfahren zur herstellung von 4-brom-anilin-derivaten
CA2168921A1 (en) 1,6-naphthyridonecarboxylic acid derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition